Roche Gets Atezolizumab Applications Rolling
This article was originally published in The Pink Sheet Daily
With the PD-L1 inhibitor under review at FDA for bladder cancer, the Swiss pharma aims to complete the rolling submission for lung cancer by the end of the quarter.
You may also be interested in...
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.